Business Combinations (Details Textual) - USD ($) $ in Thousands |
8 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Apr. 18, 2021 |
Dec. 31, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
Statement [Line Items] | |||||
Acquisition costs and non-recurring expenses | $ 200 | ||||
Payments to acquire businesses, gross | 7,976 | $ 0 | $ 0 | ||
OB Healthcare | |||||
Statement [Line Items] | |||||
Payments to acquire businesses, gross | $ 6,100 | $ 400 | |||
OB Healthcare | Other Current Liabilities | |||||
Statement [Line Items] | |||||
Contingent consideration | $ 800 | ||||
General and Administrative Expense | |||||
Statement [Line Items] | |||||
Pro forma acquisition cost and non-recurring expense | $ 500 |
X | ||||||||||
- Definition The pro forma acquisition cost and non-recurring expense for a period as if the business combination or combinations had been completed at the beginning of the period. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|